BioNTech SE is accelerating its transformation into a diversified biopharmaceutical company, with a clear focus on building a robust oncology pipeline. The company’s strategy, combining strategic partnerships, ambitious clinical goals, and a solid financial foundation, is drawing renewed attention from investors and analysts alike.
The stock has responded favorably to recent developments. Trading at approximately $99, BioNTech shares have gained roughly 8-10% over recent weeks. Analyst sentiment remains constructive, with the average 12-month price target sitting around $133 to $135, suggesting significant upside potential from current levels.
A key pillar of BioNTech’s expansion is its newly announced clinical collaboration with Boehringer Ingelheim, formalized on April 9, 2026. The partnership aims to evaluate a combination immunotherapy for advanced-stage small cell lung cancer, an aggressive malignancy with limited treatment options. BioNTech will contribute its bispecific antibody, Pumitamig, which targets PD-L1 and VEGF-A. This asset has already shown promise in a global Phase II study, demonstrating a confirmed objective response rate of 76.3% and a disease control rate of 100% when combined with chemotherapy. Boehringer Ingelheim will add its DLL3-targeting T-cell engager, Obrixtamig, and will lead regulatory efforts for the joint Phase Ib/II trial. Patient enrollment is slated to begin in the second half of 2026.
Beyond oncology, BioNTech continues to advance its infectious disease portfolio. The company has successfully completed the early-stage clinical study for its mRNA-based malaria vaccine candidate, BNT165e. The trial, which began in late 2023, faced a temporary clinical hold by the U.S. FDA in March 2025. After addressing the agency’s requirements, BioNTech resumed and has now formally concluded the study, with data analysis underway.
Should investors sell immediately? Or is it worth buying BioNTech?
Financing this ambitious clinical push is a top priority. BioNTech plans to seek shareholder approval for a significant capital increase, dubbed “Authorized Capital 2026,” which would enable the issuance of up to approximately 129.5 million new shares. This potential dilution is intended to fund the company’s evolution into a multi-product entity, particularly supporting late-stage clinical development. Management is targeting an aggressive timeline, aiming to have 15 active Phase 3 studies in oncology by the end of 2026. This portfolio spans immunomodulators, antibody-drug conjugates (ADCs), and mRNA cancer immunotherapies.
The company enters this next growth phase from a position of notable financial strength. BioNTech’s war chest holds approximately €17.2 billion in cash and marketable securities, providing substantial resources to execute its strategy without relying solely on new equity.
Investors will get a detailed update on the company’s progress at the Annual General Meeting scheduled for May 15, 2026. A major near-term catalyst is also on the horizon: BioNTech plans to submit its first Biologics License Application (BLA) outside the COVID-19 realm later in 2026. This filing will be for its HER2-targeting ADC as a treatment for endometrial cancer, marking a pivotal step toward commercializing its oncology pipeline.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 17 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 17.
BioNTech: Buy or sell? Read more here...
